SEBI Reg. Investment Advisor

Download App
Help Center Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Solvay Pharma India Ltd. (Amalgamated) (532447)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532447 NSE: Pharmaceuticals & Drugs | Small Cap | Solvay Pharma Share Price

BSE Share Price
Not Listed

Solvay Pharma India Ltd. (Amalgamated) (532447)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532447 NSE: Pharmaceuticals & Drugs | Small Cap | Solvay Pharma Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹1,081 Cr.
Current Price
₹0
52-Week Low / High
₹1,665 / 3,200
TTM EPS
₹100.5
TTM Sales
₹312 Cr.
Book Value per Share
₹350.8
P/E Ratio
21.30
Industry PE
49.8
Price to Book (P/B)
6.11
Price to Sales (P/S)
3.46
EV/EBITDA
12.25
Dividend Yield
INF%
Profitability Efficiency
Return on Equity (ROE)
34.36%
Return on Capital Employed (ROCE)
51.25%
Return on Assets (ROA)
26.25%
Operating Profit Margin
24.8%
Net Profit Margin
17.25%
Gross Profit Margin
26.2%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
21.93%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
21.58%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
27.03%
Asset Quality
Promoter Holding
88.85%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹172 Cr.
Equity
₹5.1 Cr.
Face Value
₹10
All Time Low / High
₹87.50 / 3599.60

Solvay Pharma India . (Amalgamated) stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation ⓘ

Mar'02Dec'02Dec'03Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10TTM
ROCE % ⓘ77.6%52.5%40.8%73.5%46.8%39.4%50.8%51.2%50.7%51.3%-

Growth Parameters ⓘ
Sales ⓘ78.182.396.6116130144168200242295312
Sales YoY Gr.-5.3%17.4%20.3%11.7%11.1%16.4%19.4%20.7%21.9%-
Adj EPS ⓘ15.920.915.534.335.137.35563.877.199.5100.5
YoY Gr.-31.9%-25.9%121.3%2.4%6.2%47.5%16.1%20.9%29.1%-
BVPS (₹) ⓘ39.669.864.7105.3134.6162.5171.9216.4257.6328.6350.8
Adj Net
Profit ⓘ		810.67.817.317.718.827.832.23950.351
Cash Flow from Ops. ⓘ1020.1-2.321.517.314.726.6-6.769.727.5-
Debt/CF from Ops. ⓘ00-1.50000000-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ15.9%17.8%20.7%21.9%
Adj EPS ⓘ22.6%23.2%21.9%29.1%
BVPSⓘ26.5%19.6%24.1%27.6%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'02Dec'02Dec'03Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10TTM
Return on
Equity % ⓘ		48.634.126.540.429.325.132.932.932.53429.6
Op. Profit
Mgn % ⓘ		16.720.117.323.723.321.526.323.524.924.925.5
Net Profit
Mgn % ⓘ		10.312.98.114.913.713.116.616.116.117.116.3
Debt to
Equity ⓘ		000.10000000-
Working Cap
Days ⓘ		7711295908595921211159585
Cash Conv.
Cycle ⓘ		2117313525282131302358

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'02Dec'02Dec'03Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10
Sales78.1361.7196.58116.15129.74144.09167.77200.34241.73294.73
Operating Expenses ⓘ + 65.2049.8980.3388.9399.58113.54123.61153.89181.52221.54
Manufacturing Costs1.931.821.991.742.122.472.723.124.154.66
Material Costs36.7224.4440.9850.4755.7863.5170.2684.98106.40119.05
Employee Cost 9.467.9113.0313.3615.1916.5117.9820.3625.7533.01
Other Costs ⓘ 17.0715.7224.3423.3626.4931.0532.6545.4445.2364.82
Operating Profit ⓘ 12.9411.8216.2427.2230.1630.5544.1646.4560.2073.19
Operating Profit Margin (%) 16.6%19.2%16.8%23.4%23.2%21.2%26.3%23.2%24.9%24.8%
Other Income ⓘ + 0.290.951.171.622.883.643.745.103.785.87
Exceptional Items ⓘ 0008.7500001.250
Interest ⓘ 0.280.120.280.180.020.080.030.0100.01
Depreciation ⓘ 0.430.584.684.684.594.594.971.334.573.20
Profit Before Tax ⓘ 12.5212.0712.4532.7328.4329.5242.9050.2160.6675.84
Tax ⓘ 4.554.514.509.3710.2110.7914.7817.4120.6324.99
Profit After Tax 7.977.567.9523.3618.2218.7328.1232.8040.0350.85
PAT Margin (%) 10.2%12.3%8.2%20.1%14.0%13.0%16.8%16.4%16.6%17.3%
Adjusted EPS (₹)15.815.015.746.336.137.155.765.079.3100.7
Dividend Payout Ratio (%)12.70%13.40%19.10%10.80%16.60%21.60%71.80%26.90%41%25.30%

Valuation of Solvay Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'02Dec'02Dec'03Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10

Equity and Liabilities

Shareholders Fund + 20.0226.4432.6753.1867.9482.0686.80109.27130.09165.93
Share Capital ⓘ 5.055.055.055.055.055.055.055.055.055.05
Reserves ⓘ 14.9721.3927.6248.1362.8977.0181.75104.22125.04160.88
Debt +003.370.270.160.040000
Long Term Debt003.370.270.160.040000
Short Term Debt0000000000
Minority Interest0000000000
Trade Payables9.6813.2713.6310.9014.3118.6217.1331.6421.5428.28
Others Liabilities ⓘ 1.477.374.326.496.536.5112.3613.4718.0923.48
Total Liabilities ⓘ 31.1747.0753.9970.8488.94107.23116.29154.37169.72217.69

Fixed Assets

Net Fixed Assets ⓘ +2.1516.7718.8914.259.807.094.412.4637.5435.66
Gross Block3.3518.3025.1825.1925.2427.0329.1327.8364.2362.43
Accumulated Depreciation1.201.536.2910.9415.4419.9424.7325.3726.6926.77
CWIP ⓘ 0.290.060000.100.0635.1500
Investments ⓘ 00.010.010.017.0114.0239.8416.6615.9336.67
Inventories7.8112.7619.8314.2517.3423.6522.7456.8433.9553.51
Trade Receivables8.295.169.1211.3812.6714.3216.6918.2215.6315
Cash Equivalents 8.818.101.6427.1235.4340.9724.396.9452.9251.15
Others Assets ⓘ 3.824.224.513.846.697.098.1518.0913.7525.71
Total Assets ⓘ 31.1747.0753.9970.8488.94107.23116.29154.37169.72217.69

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'02Dec'02Dec'03Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10
Cash Flow From Operating Activity ⓘ + 9.9815.10-2.3121.5117.2514.7026.57-6.6569.6727.47
PBT ⓘ 12.5212.0712.4523.9828.4329.5242.9050.2160.6675.84
Adjustment ⓘ 0.630.064.704.262.752.762.98-0.680.662.32
Changes in Working Capital ⓘ 1.527.59-14.830.95-3.8-4.32-4.35-36.0529-23.8
Tax Paid ⓘ -4.68-4.62-4.62-7.68-10.13-13.26-14.97-20.12-20.65-26.90
Cash Flow From Investing Activity ⓘ + -0.83-14.63-6.108.95-5.98-5.60-24.241.12-9.09-17.49
Capex -0.83-14.98-6.758.70-0.14-1-2.28-27.16-10.80-1.51
Net Investments 0000-7-7.01-25.6823.790.74-20.74
Others ⓘ 00.340.650.251.162.413.724.480.964.76
Cash Flow From Financing Activity ⓘ + -0.96-1.131.96-4.99-2.96-3.56-18.90-11.92-14.60-11.76
Net Proceeds from Shares ⓘ 0000000000
Net Proceeds from Borrowing ⓘ 003.37-3.10000000
Interest Paid ⓘ -0.28-0.12-0.28-0.18-0.02-0.01-0000
Dividend Paid ⓘ -0.62-1.01-1-1.49-2.50-3-16.52-7.52-15.02-10.04
Others ⓘ -0.060-0.13-0.22-0.44-0.55-2.38-4.410.43-1.72
Net Cash Flow ⓘ 8.19-0.67-6.4625.478.315.54-16.57-17.4545.98-1.78

Financial Ratio

PARTICULARSMar'02Dec'02Dec'03Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10
Ratios
ROE (%)57.132.5326.8954.4230.0824.9733.333.4633.4534.36
ROCE (%)77.652.4840.7573.5346.8139.4250.8451.2350.6951.25
Asset Turnover Ratio3.421.752.122.051.781.611.641.571.531.56
PAT to CFO Conversion(x)1.252-0.290.920.950.780.94-0.21.740.54
Working Capital Days
Receivable Days30.1035.8024.4029.3030.9031.3030.9029.9024.9018.50
Inventory Days28.3054.7055.7048.7040.6047.5046.2068.2066.8052.90
Payable Days54.50126.6084.6066.7073.9082.5084.70104.6091.2076.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Solvay Pharma India Ltd. (Amalgamated) FAQs

The current trading price of Solvay Pharma on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Solvay Pharma stood at ₹1,081.4 Cr

The latest P/E ratio of Solvay Pharma as of 31-Dec-1969 is 21.30.

The latest P/B ratio of Solvay Pharma as of 31-Dec-1969 is 6.11.

The 52-week high of Solvay Pharma is ₹3,200 and the 52-week low is ₹1,665.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Solvay Pharma is ₹312 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Solvay Pharma India Ltd. (Amalgamated)

Solvay Pharma India (SPIL) was incorporated in 2002 as a consequence of the demerger of pharma business of Duphar-Interfran. Solvay Pharma India has presence in the field of women’s health, gastroenterology, mental health and influenza vaccines. Deeply rooted in these specialty segments SPIL is a leader with its competent products and innovative solutions. The company strives to provide the health care industry with newer & quality products that are effective and safe in areas where clinical need for treatment is most urgent.

Products

Women Health

  • arachitol®
  • duphaston®
  • duvadilan®
  • Utrogestan®
  • puregon*
  • nugon*
  • clome*
  • Oestrogel®
  • bcrip*

Psychiatry / ENT / Neurology

  • solspre*
  • vertin®
  • uvox*
  • ebasil*

Gastroenterology

  • duphalac®
  • creon®
  • colospa®
  • eldicet®
  • pankreoflat®
  • udiliv®

Vaccines

  • influvac®

General

  • duodil®
  • collosal iodine oral

Solvay is an international chemical and pharmaceutical group with headquarters in Brussels. In India, Solvay is present in the pharmaceutical sector through its group company Solvay Pharma India. The company is head quartered at Mumbai and employs more than 450 people throughout India. It operates through two sales divisions and reaches out to its customers across the country through more than 1100 distributors. Currently the company structures itself into 2 Divisions, aided with its dedicated sales force and focusing on specialties and super specialties.

With research as the backbone, most of the products are brand leaders in their respective therapeutic segments. High level of scientific interaction, intense product knowledge enables the team to meet the ever-changing needs of medicine. New Product Introduction is advocated actively and the company plans to launch new products each year in either divisions.

You have 3 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: